Evidence map›Paper›PMID 41383089›Full record

Observational studyThoracic cancer2025

Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study.

Yechan Song, Myeong Geun Choi, Yeon Joo Kim, Jae Cheol Lee, Wonjun Ji, In-Jae Oh, Sung Yong Lee, Seong Hoon Yoon, Shin Yup Lee, Jeong Eun Lee and 3 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yechan SongDepartment of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Myeong Geun ChoiDepartment of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-3538-1993
Yeon Joo KimDepartment of Pulmonology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0116-7681
Jae Cheol LeeDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Wonjun JiDepartment of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-7164-2770
In-Jae OhDepartment of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
Sung Yong LeeDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8693-5792
Seong Hoon YoonDivision of Pulmonology, Allergy, and Critical Care Medicine, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
Shin Yup LeeDepartment of Internal Medicine, Kyungpook National University, School of Medicine, Daegu, Korea.ORCID https://orcid.org/0000-0002-2121-7335
Jeong Eun LeeDivision of Pulmonology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
Eun Young KimDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Ho Young KimDivision of Hematology and Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Chang-Min ChoiDepartment of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Funding

Roche
6 · The paper itself

Abstract

backgroundWe previously reported the short-term real-world effectiveness and safety of first-line atezolizumab combined with chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). This study provides an updated analysis of the effectiveness, prognostic factors, and subsequent treatment patterns in first-line immunochemotherapy.

methodsThis prospective multicenter observational study enrolled patients with ES-SCLC, diagnosed at seven university hospitals throughout Korea, between June 2021 and August 2022. Primary outcomes were 1-year overall survival (OS) and progression-free survival (PFS), whereas secondary outcomes included OS, objective response rate, disease control rate, second progression-free survival, and safety, evaluated based on established clinical guidelines.

resultsA total of 100 ES-SCLC patients (median age, 69 years) were enrolled, with a median follow-up duration of 26.0 months. The median PFS and OS were 6.2 and 17.1 months, respectively, with a 1-year OS rate of 62.5%. Favorable prognostic factors for OS included partial response (PR) and stable disease (SD) as the best responses (SD: hazard ratio (HR), 0.79; PR: HR, 0.38) and a longer platinum-free interval (HR 0.84). Brain radiotherapy significantly improved OS in patients with brain metastases, whereas thoracic radiotherapy during first-line treatment tended to prolong survival in patients who responded to systemic treatment. Patients receiving second-line treatment after progression presented a significantly longer OS than did those receiving only best supportive care.

conclusionThis study outlined the real-world effectiveness and safety of first-line atezolizumab immunochemotherapy for ES-SCLC patients over an extended follow-up, noting that local treatment and post-progression therapy were associated with improved survival.

Indexed as

Antibodies, Monoclonal, HumanizedLung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm StagingPrognosisProspective StudiesAntibodies, Monoclonal, Humanizedatezolizumabatezolizumabreal‐worldsmall cell lung carcinoma

Identifiers

PMID41383089
PMCPMC12698942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.